Establishing Prognostic Models for Intrahepatic Cholangiocarcinoma Based on Immune Cells

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2024 Oct 30

PMID 39473952

Authors

Zhuo-Ran Wang

Cun-Zhen Zhang

Zhan Ding

Yi-Zhuo Li

Jian-Hua Yin

Nan Li

Affiliations

Soon will be listed here.

Abstract

Background: Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor that is challenging to treat and manage and current prognostic models for the disease are inefficient or ineffective. Tumor-associated immune cells are critical for tumor development and progression. The main goal of this study was to establish models based on tumor-associated immune cells for predicting the overall survival of patients undergoing surgery for ICC.

Aim: To establish 1-year and 3-year prognostic models for ICC after surgical resection.

Methods: Immunohistochemical staining was performed for CD4, CD8, CD20, pan-cytokeratin (CK), and CD68 in tumors and paired adjacent tissues from 141 patients with ICC who underwent curative surgery. Selection of variables was based on regression diagnostic procedures and goodness-of-fit tests (PH assumption). Clinical parameters and pathological diagnoses, combined with the distribution of immune cells in tumors and paired adjacent tissues, were utilized to establish 1- and 3-year prognostic models.

Results: This is an important application of immune cells in the tumor microenvironment. CD4, CD8, CD20, and CK were included in the establishment of our prognostic model by stepwise selection, whereas CD68 was not significantly associated with the prognosis of ICC. By integrating clinical data associated with ICC, distinct prognostic models were derived for 1- and 3-year survival outcomes using variable selection. The 1-year prediction model yielded a C-index of 0.76 95% confidence interval (95%CI): 0.65-0.87 and the 3-year prediction model produced a C-index of 0.69 (95%CI: 0.65-0.73). Internal validation yielded a C-index of 0.761 (95%CI: 0.669-0.853) for the 1-year model and 0.693 (95%CI: 0.642-0.744) for the 3-year model.

Conclusion: We developed Cox regression models for 1-year and 3-year survival predictions of patients with ICC who underwent resection, which has positive implications for establishing a more comprehensive prognostic model for ICC based on tumor immune microenvironment and immune cell changes in the future.

References

Moazzam Z, Alaimo L, Endo Y, Lima H, Ruzzenente A, Guglielmi A . Combined Tumor Burden Score and Carbohydrate Antigen 19-9 Grading System to Predict Outcomes Among Patients with Intrahepatic Cholangiocarcinoma. J Am Coll Surg. 2023; 236(4):804-813. DOI: 10.1097/XCS.0000000000000557. View

Scott A, Wong P, Melstrom L . Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma. Surgery. 2023; 174(1):113-115. DOI: 10.1016/j.surg.2023.01.019. View

Zheng Y, Huang N, Kuang S, Zhang J, Zhao H, Wu J . The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery. Cancer. 2022; 129(3):393-404. PMC: 10099237. DOI: 10.1002/cncr.34552. View

Zheng B, Ma J, Tian L, Dong L, Song G, Pan J . The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clin Transl Med. 2020; 10(1):45-56. PMC: 7239312. DOI: 10.1002/ctm2.11. View

Atanasov G, Hau H, Dietel C, Benzing C, Krenzien F, Brandl A . Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer. 2015; 15:790. PMC: 4620011. DOI: 10.1186/s12885-015-1795-7. View

Ye Y, Xin H, Li J, Li N, Pan S, Chen L . Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma. Clin Mol Hepatol. 2024; 30(4):914-928. PMC: 11540385. DOI: 10.3350/cmh.2024.0296. View

Garcia-Martinez E, Gil G, Chaves Benito A, Gonzalez-Billalabeitia E, Vicente Conesa M, Garcia Garcia T . Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014; 16(6):488. PMC: 4303200. DOI: 10.1186/s13058-014-0488-5. View

Chen B, Lu M, Chen Q, Zou E, Bo Z, Li J . Systematic profiling of mitochondria-related transcriptome in tumorigenesis, prognosis, and tumor immune microenvironment of intrahepatic cholangiocarcinoma: a multi-center cohort study. Front Genet. 2024; 15:1430885. PMC: 11310173. DOI: 10.3389/fgene.2024.1430885. View

Liau M, Toh E, Shelat V . -Current Understanding of the Neglected Hepatobiliary Parasite. Pathogens. 2023; 12(6). PMC: 10301378. DOI: 10.3390/pathogens12060795. View

10.

Verma N, Wong B, Poh Z, Udayakumar A, Verma R, Goh R . Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint. EBioMedicine. 2022; 83:104216. PMC: 9403334. DOI: 10.1016/j.ebiom.2022.104216. View

11.

Zhao C, He C, Lu J, Huang X, Chen C, Lin X . Progression Patterns and Post-Progression Survival in Recurred Intrahepatic Cholangiocarcinoma Patients: A Novel Prognostic Nomogram Based on Multicenter Cohorts. Front Oncol. 2022; 12:832038. PMC: 9033166. DOI: 10.3389/fonc.2022.832038. View

12.

Trailin A, cervenkova L, Ambrozkiewicz F, Ali E, Kasi P, Palek R . T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis. Cancers (Basel). 2022; 14(3). PMC: 8833821. DOI: 10.3390/cancers14030604. View

13.

Deng M, Li S, Fu X, Yan X, Chen J, Qiu Y . Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell Int. 2021; 21(1):371. PMC: 8273972. DOI: 10.1186/s12935-021-02081-w. View

14.

Shi J, Gao Q, Wang Z, Zhou J, Wang X, Min Z . Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin Cancer Res. 2013; 19(21):5994-6005. DOI: 10.1158/1078-0432.CCR-12-3497. View

15.

Pocock S, Clayton T, Altman D . Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002; 359(9318):1686-9. DOI: 10.1016/S0140-6736(02)08594-X. View

16.

Mori H, Bolen J, Schuetter L, Massion P, Hoyt C, Vandenberg S . Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence. J Mammary Gland Biol Neoplasia. 2021; 25(4):417-432. PMC: 7960613. DOI: 10.1007/s10911-021-09479-2. View

17.

Chen L, Huang H, Huang Z, Chen J, Liu Y, Wu Y . Prognostic values of tissue-resident CD8T cells in human hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World J Surg Oncol. 2023; 21(1):124. PMC: 10077621. DOI: 10.1186/s12957-023-03009-6. View

18.

Hsu C, Ou D, Bai L, Chen C, Lin L, Huang S . Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer. 2021; 10(4):346-359. PMC: 8339511. DOI: 10.1159/000515305. View

19.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

20.

Buettner S, Galjart B, van Vugt J, Bagante F, Alexandrescu S, Marques H . Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017; 116(8):1085-1095. DOI: 10.1002/jso.24759. View